Approved indications: Airsupra is FDA-approved for the as-needed treatment or prevention of bronchoconstriction and to reduce the risk of asthma exacerbations in adults (18 years and older) with asthma; it is not approved as a stand-alone daily maintenance inhaler, for children, or for COPD.

Use in practice: It is intended to be used when symptoms start or before known triggers (such as exercise) to open the airways and, through the steroid component, to treat airway inflammation at the same time.

Off-label uses: There are currently no widely established off-label indications with strong evidence; some clinicians may individualize use in specific asthma phenotypes or age groups, but this is outside U.S. labeling and should be done only under specialist guidance.

Efficacy expectations: Symptom relief from the albuterol component typically begins within minutes, while the budesonide component reduces airway inflammation and risk of severe attacks with repeated use over time.

Clinical outcomes: In clinical trials, adults using Airsupra as needed had a substantially lower risk of severe asthma exacerbations requiring systemic steroids, emergency visits, or hospitalization compared with using albuterol alone.

Comparison to similar drugs: Compared with short-acting beta-agonist (SABA) rescue inhalers used alone, Airsupra adds an inhaled corticosteroid at the time of symptom worsening, which better protects against severe attacks; direct head-to-head data versus other reliever-based strategies (such as ICS formoterol regimens) are limited, so choice among them is usually based on overall asthma plan and clinician preference.

Typical adult dose: The recommended dose for adults with asthma is 2 inhalations (puffs) by mouth as needed for symptoms, which together provide 180 mcg of albuterol and 160 mcg of budesonide; do not use more than 6 doses (12 puffs) in any 24-hour period.

How to take it: Shake the inhaler well before each use, breathe out fully, place the mouthpiece in your mouth with lips sealed, begin a slow deep breath while pressing down on the canister to release the spray, then hold your breath for about 10 seconds before exhaling; repeat for the second puff, and rinse your mouth with water and spit after the dose.

Priming and re-priming: Prime the inhaler before first use by releasing several test sprays into the air away from your face as described in the patient instructions, and re-prime if it has not been used for more than 7 days, has been dropped, or after cleaning.

Use pattern: Airsupra is taken only as needed for relief or prevention of symptoms, not on a fixed schedule, and it should not be relied on as the sole treatment for severe, rapidly worsening asthma or status asthmaticus.

Special instructions: Do not use additional albuterol rescue inhalers on top of Airsupra unless your clinician specifically tells you to, and seek medical review if you find you need the inhaler more frequently than usual, as this can be a sign of poorly controlled asthma.

Missed doses: Because Airsupra is used as needed, there is no routine “missed dose”; if you forgot to use it when symptoms started, take your usual 2 puffs when you notice symptoms, but do not double doses to make up for an earlier missed use.

Overdose: Taking more than the prescribed amount can cause symptoms such as chest pain, very fast or pounding heartbeat, severe tremor, nervousness, weakness, low potassium, or high blood sugar; if overdose is suspected or symptoms are severe, stop using the inhaler and seek emergency medical care or contact poison control right away.

Common side effects: The most common side effects include headache, cough, hoarseness or difficulty speaking, throat irritation, and oral thrush (a fungal infection in the mouth); these are usually mild to moderate and may appear soon after starting treatment.

Reducing local side effects: Rinsing your mouth with water and spitting it out after each use, and not swallowing the rinse, helps lower the chance of oral thrush and hoarseness.

Serious or rare adverse effects: Serious problems that need immediate medical attention include sudden worsening wheeze or trouble breathing right after using the inhaler (paradoxical bronchospasm), signs of severe allergy such as rash, swelling of face or throat, or trouble swallowing, chest pain, very fast or irregular heartbeat, severe dizziness, or fainting.

Steroid-related risks: With frequent or high cumulative doses over time, budesonide may contribute to systemic corticosteroid effects such as weakened immune response to infections, adrenal suppression, reduced bone mineral density, eye problems (glaucoma or cataracts), and, in general with inhaled steroids, growth effects in children (though Airsupra is not approved for patients under 18).

Conditions needing caution: Use with extra caution and closer medical supervision if you have heart disease, high blood pressure, arrhythmias, a history of stroke, hyperthyroidism, seizures, diabetes, osteoporosis, active or latent infections (including tuberculosis), or significant liver disease.

Pregnancy and breastfeeding: Human data with this exact product are limited; inhaled budesonide is generally considered one of the better-studied corticosteroids in pregnancy, but Airsupra should still be used in pregnancy or while breastfeeding only if the expected benefit justifies potential risks, after discussion with your clinician.

Age limits: Airsupra is approved only for adults 18 years of age and older; safety and effectiveness in younger patients have not been established.

Relative safety compared with other options: When used as directed, the overall safety profile is similar to other inhaled albuterol and budesonide products, and combining an inhaled steroid with rescue therapy may reduce the long-term risks seen with frequent SABA-only use.

Reporting side effects and safety updates: If you think you are having a side effect, contact your healthcare provider; side effects can also be reported directly to the FDA through the MedWatch program (online or by phone) and to the manufacturer, and current safety communications and any recalls can be checked through the FDA or by asking your pharmacist.

Prescription drug interactions: Other inhaled or oral beta-agonists (such as additional albuterol products) can add to side effects like rapid heartbeat and tremor; nonselective beta-blockers (for example, propranolol) may reduce the effect of albuterol and can trigger bronchospasm; monoamine oxidase inhibitors (MAOIs), some tricyclic antidepressants, and certain anesthetics can increase the risk of serious cardiovascular reactions with albuterol.

Corticosteroid interactions: Strong CYP3A4 inhibitors (such as ketoconazole, itraconazole, clarithromycin, some HIV protease inhibitors, and cobicistat-containing products) can raise systemic budesonide levels and increase the risk of steroid-related side effects, especially with frequent use or high cumulative doses.

Other medicines and supplements: Diuretics that lower potassium (like loop or thiazide diuretics) and other drugs that affect potassium or heart rhythm (including digoxin and some antiarrhythmics) may interact with albuterol by worsening low potassium or altering heart rhythm; stimulant drugs and high caffeine intake can add to nervousness or palpitations.

OTC medicines, foods, alcohol: Many over-the-counter cold and allergy products contain decongestants that act as stimulants and may increase heart-related side effects when combined with Airsupra, so labels should be checked carefully; food interactions are minimal, but frequent grapefruit juice or other strong CYP3A4-related foods may modestly increase steroid exposure; alcohol has no direct interaction but can worsen asthma or interact with other medicines you take.

Conditions requiring precautions: Use with special caution if you have coronary artery disease, heart failure, arrhythmias, high blood pressure, hyperthyroidism, seizure disorders, diabetes, osteoporosis, active or latent infections (including tuberculosis), or significant hepatic impairment, and discuss these conditions with your clinician before starting Airsupra.

Diagnostic and procedural considerations: Let anesthesiologists and other procedural clinicians know you use an albuterol-containing inhaler, since combining frequent beta-agonist use with certain inhaled anesthetics can increase arrhythmia risk.

Monitoring needs: People who use Airsupra frequently or who have relevant risk factors may need periodic checks of asthma control (symptoms and lung function), heart rate and blood pressure, blood glucose and potassium in some cases, bone health and eye exams for long-term high corticosteroid exposure, and review of inhaler technique and dose counter use.

Q: What is Airsupra used for?
A: Airsupra is used by adults with asthma, 18 years and older, as a rescue-style inhaler taken as needed to relieve or prevent bronchoconstriction and to lower the risk of asthma attacks, rather than as a daily maintenance-only inhaler.

Q: Is Airsupra a rescue inhaler, a controller, or both?
A: Airsupra is designed as a reliever inhaler that you use when you have symptoms or before triggers, but it also delivers an inhaled steroid with each use, so it provides some controller benefit at the same time instead of giving bronchodilator-only rescue treatment.

Q: How quickly does Airsupra work and how long does it last?
A: The albuterol component usually begins to ease breathing within minutes, with effects lasting a few hours, while the budesonide component works more slowly to reduce inflammation and helps cut the risk of severe attacks when used repeatedly over time.

Q: Can Airsupra replace my daily inhaled steroid or other controller medicine?
A: Some adults with well-designed asthma action plans may be able to use Airsupra as their main reliever strategy, but many people will still need a separate daily controller inhaler; do not stop or change your regular asthma medicines without a plan made with your clinician.

Q: How often is too often to use Airsupra?
A: Needing it more than occasionally, or using more than the maximum of 12 puffs (6 doses) per day, suggests your asthma is not well controlled and you should contact your healthcare provider promptly, especially if symptoms are worsening or not relieved.

Q: Can children or teenagers use Airsupra?
A: Airsupra is currently approved only for adults 18 years and older, and its safety and effectiveness in children or adolescents have not been established, so other inhaler options are usually chosen for younger patients.

Q: Is Airsupra safe during pregnancy or breastfeeding?
A: Experience with inhaled budesonide in pregnancy is relatively reassuring, but specific data with this exact combination are limited, so the decision to use Airsupra during pregnancy or while breastfeeding should be made with your clinician after weighing your asthma severity and alternative options.

Storage: Store Airsupra at room temperature 68F to 77F (20C to 25C) in a dry place away from heat, direct sunlight, and humidity, and keep it in the unopened foil pouch until you are ready to use it.

Handling: Keep the inhaler out of the reach of children, do not freeze it, do not puncture the canister, and do not use or store it near open flames or temperatures above about 120F because the pressurized canister may burst.

Disposal: Discard the inhaler in household trash when the dose (puff) counter reaches 0 or 12 months after opening the foil pouch, whichever comes first; do not burn or incinerate the canister, and follow any local instructions from your pharmacist or waste service for aerosol products.